23 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 BIO INTERNATIONAL CONVENTION Tjoapack continuously invests in infrastructure and technology aligned with industry shifts toward biologics and patient-centric drug delivery. By proactively expanding injectable packaging capabilities and validating GMP-compliant cold chain storage, Tjoapack ensures it meets both current and future demand. The organization also emphasizes speed, compliance, and flexibility, critical success factors in today’s dynamic pharmaceutical landscape. This positions Tjoapack as a responsive and forward-thinking partner for global supply chains. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? The pharmaceutical market faces increasing demand for injectable and temperature-sensitive therapies, coupled with the need for supply chain resilience and regulatory compliance. Tjoapack addresses these challenges by: - Expanding high-throughput, automated packaging lines for sterile products - Scaling GMP-qualified cold chain capacity in both the U.S. and Europe - Diversifying packaging formats to support a range of delivery systems - These steps help mitigate bottlenecks, improve supply chain continuity, and enhance service delivery for clients operating in a highly regulated and fast-evolving market What new products or innovations is your company showcasing at BIO 2025 this year? Specialists from our Sterile Manufacturing, Clinical Services, and Commercial Packaging teams will be at BIO to showcase our end-to-end solutions that support every stage of the drug development lifecycle. What are you hoping to achieve from the event? Connecting with industry leaders, forming new partnerships and showcasing our capabilities are our top three goals. We’re most excited about conversations that push the industry forward — especially around navigating sterile manufacturing challenges, global supply strategies, and sustainable packaging solutions in pharma. That’s where we believe we can contribute most meaningfully. How does your company stay ahead of industry trends and developments in the pharmaceutical sector? It’s a mix of staying connected and staying curious. Our teams engage frequently with our clients, regulatory agencies, and supply chain partners to identify new developments and how they might impact our industry. We also participate in several industry associations to ensure we are hearing the very latest on technology, equipment, or regulatory-related updates. We’re always looking ahead to where the industry is going, so we can anticipate and plan for our clients’ needs today, and in the future. What challenges are you currently facing in the pharmaceutical market, and how is your organisation addressing them? Like many in the industry, we’re navigating ongoing supply chain complexities, rising costs, and increasing regulatory demands. There is increasing volatility in supply chains which can potentially impact our ability to deliver on time for our clients. We offset that risk by using AI that gives us a high degree of supply chain visibility and allows us to model mitigation plans. We are investing in more resilient operations—through digitalization, strategic sourcing, and strengthening our global network of capabilities. Sharp also has a strong presence in the US, the EU and the UK, which gives us the ability to offer capabilities within those local markets and when necessary, to source regionally where it makes sense for our clients. That gives us greater flexibility in what is a very dynamic market for exports globally. JEFF BENEDICT Chief Commercial Officer Sharp ROBERT CORNOG Senior Director, Product Development Quotient Sciences KEVIN SCHAAB Senior Drug Development Consultant Quotient Sciences
RkJQdWJsaXNoZXIy MjY2OTA4MA==